

# Contract Manufacturing

From Development to Commercial Supply



# Content

1. Who we are?
2. Why partner with EVA Pharma?
3. Comprehensive Development & Manufacturing Expertise.
4. Diverse Manufacturing Solutions
5. Manufacturing Capabilities
6. Sustainable Impact

## Who are we?

We're your Contract Manufacturing partner, driven by one clear purpose: expanding patient access to high-quality medicines. With a reliable, agile, and cost-effective platform, we bridge unmet medical needs while ensuring every product is delivered with excellence, compliance, and care.





# Why partner with EVA Pharma

## EVA's Way of Work



**Project Excellence Office**



**Right First Time**



**Expert-Driven Solutions**



**Lifecycle Innovation**



**Global Presence  
for Local Patients**

With agility & synergism, our dedicated PMO ensures seamless communication, keeping your project on track from start to finish.

Through process optimization, we deliver efficiency and speed without compromising quality.


With proactive technical expertise & problem-solving mindset, we anticipate any challenge and act fast to land your project.

Through continuous lifecycle management and file upgrade, we enhance product quality & compliance.

With a proven global experience in local markets, we help your products reach patients more efficiently.

# Comprehensive Development & Manufacturing Expertise

We deliver end-to-end solutions that transform ideas into market-ready products with speed and precision. We combine scientific excellence with operational discipline to efficiently advance your concepts from development to scalable, compliant manufacturing. Every step is guided by our commitment to quality and reliability, ensuring we deliver not just a product, but a testament to our patient-centric core value.





# Diverse Manufacturing Solutions

Pilot area

Process	Machines	Capacity
Wet granulation	High shear Mixer granulator (Small VG)	1- 7 kg
	Binder oven	0.5 - 15 kg
	GPCG-3	0.5 - 5 kg
Dry granulation	Greteis compactor	35 kg - 5kg/hr
Compression (monolayer)	Ronchi	3000 - 15000 tabs/hr
Compression (bilayer)	Karnavati	2100- 14700 tabs/hr
Capsule filling	Bonapace Cap XI 10	1000- 3000 caps/hr
Blending	V-shaped Blender	1-10 kg
	Cyclomix	150000 capsule/hr
Coating	Akopan-5 coater	1-4 kg
Oscillating Miller	Erweka Miller	1- 10kg/hr
Miller	Glatt Miller	3-15 kg/hr
Sieving	Vibro sifter	5000 sachet/hr
Stirrer	IKA- stirrer	25 - 50 kg
Sachet filling	Kadyco sealing machine	50 -500 sachet/hr
Blistering	Marchesini	250 - 2500 strips /hr
Nanofiber-based patches	Electrospinning	EL Marco Nanospider NS-LAB
Pilot Production Capacity per Year		126,225,000 Tablets
		12,750,000 Capsules
		2,125,000 Sachets
		10,625,000 Blisters



# Diverse Manufacturing Solutions

Category	Line	Capacity	Description
Sterile Fill and Finish	Metabolic-health biologics	100M+ cartridges, 144M+ vials	Large-scale biologics production, supporting global supply of critical therapies and vaccines including an end-to-end insulin manufacturing.
	BFS	51M eye-drops	Blow-Fill-Seal technology for ophthalmic solutions with flexible formats (multi & uni-dose)
	Vials	17.85M vials (incl. lyophilized)	Specialized in sterile vial production with lyophilization expertise.
	Ampoules	90M ampoules	High-volume sterile ampoule manufacturing for diverse therapeutic areas.
	β-Lactams	30M vials	Dedicated area for sterile β-Lactams manufacturing.





# Diverse Manufacturing Solutions

Category	Line	Capacity	Description
Solid Dosage forms	Immunosuppressants	270M tablets, 150M capsules	High-containment facility for immunosuppressants, anti-neoplastic & high-potency medicines with strict safety and quality controls.
	DPI	330M capsules	Dry Powder Inhaler manufacturing for respiratory therapies at commercial scale.
	Multi-layer tablets	630M tablets	Expertise in double- and triple-layer tablet technologies for complex formulations.
	Hard gelatin	1.5B capsules	Large-scale hard gelatin capsule production across therapeutic areas.
	Soft gelatin	150M capsules	Specialized soft gel line.
	Tablets	4B+	High-volume tablet production with robust scalability.
	Capsules	1.9B+	Advanced capsule production capacity across multiple formulations.
	Powder	42M units	Powder formulations for oral and other solid dosage applications.
	ODT	4B+	Orally disintegrating tablets with patient-friendly delivery at massive scale.

# Diverse Manufacturing Solutions


Category	Line	Capacity	Description
Special Formulation	ODF	130M films	Oral dissolving films – innovative patient-centric dosage forms.
	Hydrogel	26M+ patches	Hydrogel formulations available.
	Transdermal patch	18M patches	Advanced transdermal systems offering controlled drug delivery.





# Global Quality; Global Health

EVA Pharma’s state-of-the-art manufacturing facilities are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple global regulatory authorities.



# Manufacturing Capabilities:

## Haram Manufacrting Complex



Producing a wide range of dosage forms.

A facility with a **capacity of 114 million medicines** per year is producing a wide range of dosage forms.





# 10th of Ramadan Manufacturing Facility



A site producing **5.2 million medicines per year** serves as the first dedicated high-containment manufacturing facility in the MENA region.

# EVA Pharma 6th of October Manufacturing Complex



A facility with a capacity of **206 million medicines per year** allows the upscaling of manufacturing capabilities to produce a wide range of dosage forms.





# EVA Pharma Research & Manufacturing Complex (Sudair, Saudi Arabia)




An industrial complex with a total output of **990 million medicines per year** aims to become a center of gravity for pharmaceutical manufacturing in the region, featuring an R&D center and five pharmaceutical factories.



# Limitless Naturals Facility



Another facility with a capacity of **26 million medicines per year** produces a diverse portfolio of **95 supplements**, including vitamins, minerals, antioxidants, and herbal products.





## Sustainable Impact:

We have a record of successful collaborations in a variety of areas, being a key provider of life - saving treatments for the most pressing health issues as HIV,HBV, HCV, COVID-19, as well as biologic treatments for diabetes in a list of low - to middle-income countries. And today we are pioneering diverse medical solutions for the Middle East & Africa, through local manufacturing and tech-transfer collaborations.

### A record of successful collaborations: Metabolic health biologics:

As part of Lilly's 30x30 initiative, Eli Lilly and EVA Pharma are collaborating to deliver a sustainable supply of human and analogue insulin to people living with type 1 and type 2 diabetes in low- to middle-income countries.

Eli Lilly is supplying API along with technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in Africa.

In December 2024, Lilly and EVA Pharma announced regulatory approval and release of locally manufactured insulin Glargine in Egypt.collaborations.



## Localizing Innovative Anti-HIV Medicines:

EVA Pharma signed a non-exclusive, royalty-free voluntary licensing agreement with Gilead, allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product.

This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility to lenacapavir in 120 high-incidence, resource-limited countries.

**EVA Pharma Signs  
Agreement with Gilead  
to Boost HIV care in  
120 countries**





# RNA-based Vaccines and Therapeutics

EVA Pharma, DNA Script, and Quantoom Biosciences have signed MoU focusing on developing a next generation, saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases from the source. The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations.




## Oncology Medications:

In collaboration with BeiGene, EVA Pharma to import, market, promote and distribute BeiGene’s flagship Oncology medicines in Egypt. By leveraging EVA Pharma’s deep expertise in distribution, medical affairs, and regional market dynamics, this collaboration aims to make these innovative options more accessible to patients in Egypt.



Innovation to sustainable access.



bd@evapharma.com